CMB International Securities analyst Jill Wu maintained a Buy rating on Giant Biogene Holding Co. Ltd. on August 29 and set a price target of HK$71.30.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jill Wu has given her Buy rating due to a combination of factors that highlight Giant Biogene Holding Co. Ltd.’s potential for continued growth. The company reported a significant increase in revenue for the first half of 2025, with a 22.5% year-over-year growth, driven by strong performance across multiple sales channels and product lines. This growth is expected to continue in the second half of the year, particularly with the anticipated recovery in online sales and influencer live-streaming initiatives.
Moreover, the company’s Comfy brand has shown resilient growth with successful portfolio expansion, and the Collgene brand is unlocking its online potential despite challenges in offline sales. The company’s strategic marketing efforts, including collaborations with leading influencers, are expected to further enhance its market presence and drive sales. Although there is some pressure on offline sales, the overall outlook remains positive, justifying the Buy rating with a revised target price based on a discounted cash flow model.
In another report released yesterday, Macquarie also maintained a Buy rating on the stock with a HK$80.00 price target.
2367’s price has also changed moderately for the past six months – from HK$62.600 to HK$53.950, which is a -13.82% drop .